Ellacor® Micro-Coring Technology® for Skin Laxity and Wrinkles
This study is looking at how the Ellacor® Micro-Coring Technology® device works on different skin types and in various treatment areas, including patients who are taking GLP-1 medications (a type of drug that helps control blood sugar and weight). The device uses tiny needles to remove very small cores of skin, which helps the skin repair itself and create new collagen. Researchers want to see what changes happen in the treated skin compared to untreated skin, and also track any side effects. You may be able to join if you are between 30 and 65 years old, have moderate to severe wrinkles on your mid and lower face, and moderate to extreme abdominal skin looseness. The study aims to enroll 10 participants.
- Study design
- This is an observational study involving a minimum of 10 and a maximum of 30 participants. It is being conducted at Tri Valley Plastic Surgery.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and outcomes will be measured at the study time frame, but the specific duration is not detailed.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Outcomesstudy time frame
Safety and Efficacy of ellacor treatment in participants with FST I-VI, inclusive of participants following treatment with GLP-1 RA There will be follow-up appointments after the initial screening and enrollment visit. Each of the assessments at follow up days are specified below: Baseline or Day 0 Day 3 Day 7 Day 30 through study completion, up to Day 90